RxDoctor Payments Data

Rita Gupta, MD

Hematology & Oncology · Clinton, MDNPI 1003857269

Payments from drug & device makers

$11,330in general payments, 2019–2025

Across 480 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$884
  • Merck$864
  • Johnson & Johnson$782
  • Pfizer$682
  • AstraZeneca$658
  • Daiichi Sankyo Inc.$483
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,10498%
  • Education$2262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis39$884
Merck41$864
Johnson & Johnson(2 entities)31$782
Pfizer32$682
AstraZeneca(2 entities)30$658
Daiichi Sankyo Inc.16$483
Astellas Pharma US Inc23$460
Genentech USA, Inc.19$441
Incyte Corporation10$320
AbbVie12$292
Seagen Inc.10$264
Takeda Pharmaceuticals U.S.A., Inc.12$264
Beigene USA, Inc.9$256
Lilly USA, LLC10$223
Sanofi7$220
Pharmaessentia USA Corporation7$212
Exelixis Inc.7$201
Eisai Inc.9$200
E.r. Squibb & Sons, L.L.C.9$182
Array Biopharma Inc9$175
Amgen9$168
Bristol Myers Squibb7$148
Pharmacyclics LLC, An Abbvie Company6$146
Rigel Pharmaceuticals, Inc.6$141
Stemline Therapeutics Inc.5$138
Regeneron Healthcare Solutions, Inc.5$138
Puma Biotechnology, Inc.7$124
Tactile Systems Technology Inc1$120
Bayer5$116
GSK5$114
Ipsen Biopharmaceuticals, Inc4$105
Gilead5$105
Genmab U.S., Inc.3$101
Taiho Oncology, Inc.4$93
Beone Medicines USA, Inc.3$92
ADC Therapeutics America, Inc.3$81
Mirati Therapeutics, Inc.2$79
EMD Serono, Inc.3$70
EUSA Pharma (US) LLC3$63
Kyowa Kirin, Inc.3$61
Sumitomo Pharma America, Inc.3$60
AVEO Pharmaceuticals, Inc.2$58
Deciphera Pharmaceuticals Inc.3$58
Sobi, Inc3$56
Heron Therapeutics, Inc.2$54
Tersera Therapeutics LLC2$54
Tempus AI, Inc2$49
Pharmacosmos Therapeutics Inc.2$47
Morphosys, US Inc.2$46
Boehringer Ingelheim2$45
Blueprint Medicines Corporation2$44
Blue Earth Diagnostics1$35
CTI Biopharma Corp.2$33
Servier Pharmaceuticals LLC2$32
Acrotech Biopharma Inc.2$31
Alnylam Pharmaceuticals Inc.2$30
Adaptive Biotechnologies Corporation1$28
Novocure Inc.1$28
Geron Corporation1$27
Sirtex Medical Inc1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,330 in reported general payments places this provider in the 50th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$3,640,353
Medicare patients
1,069
Services billed
186,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide20$309,097
Lenalidomide19$308,191
TukysaTucatinib12$308,175
VerzenioAbemaciclib13$199,701
JakafiRuxolitinib Phosphate24$164,516
SprycelDasatinib14$135,677
EliquisApixaban134$104,034
XareltoRivaroxaban33$27,904
Exemestane72$13,646
Anastrozole245$4,016
Letrozole157$2,816
Megestrol Acetate18$1,212
Hydroxyurea29$441
Tamoxifen Citrate13$369
Ibandronate Sodium15$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$148$309,09720 claims
Seagen Inc.Tukysa$264$308,17512 claims
Lilly USA, LLCVerzenio$223$199,70113 claims
Incyte CorporationJakafi$320$164,51624 claims
E.r. Squibb & Sons, L.L.C.Sprycel$182$135,67714 claims
PfizerEliquis$682$104,034134 claims
Johnson & JohnsonXarelto$782$27,90433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 242 hematology & oncology providers in Maryland.

Other hematology & oncology in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →